Member Info for trytryandagain

Well it's been one hell of a week and an absolute turnaround not only for the chat board but also for the business. You can seem to spend months asking yourself when it's quiet, when is our news and will it get the reaction expected or ignored by the market. I think it's fair to say the market noticed us and it makes all those days researching and reading again and again and questioning your belief worth it. I very much look forward to what happens next and what has to be a marked increase in news flow, it will certainly be nice to see the first RNS of how this newly authorised product has been delivered to the end user.

Thanks readicant

Formal any chance you have time to explain gad free for the newer guys here, I would but am exhausted from the latest product and digging to try and explain. Gad free is a massive cost saving on current practice and due to gad unknown long term effects in the organs it should also be adopted as well as our latest gift :-)

I would say my target is a tenner (over next two years) and I got scoffed at for that LMAO. T/O is a real concern but the CEO will surely want to beat his best T/O price of 150 million just for the sake of it if nothing else!

Popped in my nose got the better of me :-) Guys and gals the SP is up 350% from 3rd November... it's doing exactly what is healthy, establishing a support going forward. This is a fantastic share and now has authority to have a fantastic turnover at very high profit, relax enjoy the news flow and the less crazy swings in the SP as it gains it's value in a more realistic way.

https://www.shortdata.co.uk/company.php?isin=JE00BD4H0R42

That's me for the day, I get up early and do my research and I see no reason to sell here so will not be part of the games that get played with the SP. I have 100% faith that this company is going to do outstanding especially in 2021, have a great day everyone and makle your mind up before the market open's what you want to do... don't get played.

The last raise over a year ago was for 500K hardly a massive sum compared to market cap now but I don't believe they need it.

No it doesn't gatto, income has been generated from 2 suite sales and already from june we had one years cash left to keep things going. The spend is very well controlled here as the article states and not a concern.

They are using the report up to June which is fair enough. We have sold two suites RNS'd since then and this new RNS dramatically increases potential revenue in a short time frame.
As you can probably tell by now, we’re not too worried about IQ-AI’s cash burn. In particular, we think its cash burn relative to its market cap stands out as evidence that the company is well on top of its spending. And even though its cash runway wasn’t quite as impressive, it was still a positive. Considering all the factors discussed in this article, we’re not overly concerned about the company’s cash burn, although we do think shareholders should keep an eye on how it develops.

J427 claimed it was his/her buy, looking at the posting history I have no reason to believe that it's a lie.

My conclusion
1) you see this as the first reliable approved non invasive solution available and hold for what should be a very quickly adopted and has the potential to become the standard of care for a significant global market.
2) concern yourself that this is a pump and dump empty shell you invested in and sell, we have all seen it and I guess when you have seen it so many times on the AIM market (which this isn't) finding a diamond can be unbelievable and you throw it out with the broken glass.
3) trade the hell out of it and hope that works better than a hold in a very limited free float company where NT is very common.
GLA, I know where I stand on this and believe what I have researched over the last two years, it's worth remembering this is just one of the companies products I am focusing on there are a lot more strings to this bow.

And in the EU from October 2020

Measurement of the HVPG by right hepatic vein catheterisation is the reference technique to assess CSPH. This method is invasive, and can often only be performed in expert centres, limiting its availability. To overcome these limitations, several non-invasive methods have been developed. The most frequently used technique is the liver stiffness measurement (LSM), using transient elastography (TE), which is strongly correlated to HVPG and is useful for the detection of CSPH, including in patients in whom liver resection is indicated.5, 6, 7 LSM-derived scores, such as the LSM-spleen-size-to-platelet ratio score (LSPS), which combines liver stiffness, spleen diameter and platelet count, have been shown to improve the detection of CSPH.8 Nevertheless, LSM has certain well-known limitations, in particular, the rate of unreliable examinations.9
It was recently shown that the diagnostic performance of the quantification of liver surface nodularity (LSN) on routine computed tomography (CT) was good for detecting CSPH and was better than numerous other non-invasive tests.10,11 The quantification of LSN is easy to obtain and can be retrospectively derived from routine CT, which is especially convenient in patients in whom liver resection is being considered.

https://www.jhep-reports.eu/article/S2589-5559(20)30081-1/fulltext

It's all good knowing that the LSN is what is desired but you need FDA approval to market and sell...oh wait we do!

https://www.rsna.org/en/news/2020/november/ydia-miller

This gives you an idea of just how important and sought after LSN is, there are many businesses looking at this approach to the problem, why is it needed and I would answer that by saying a doctor can only help their patients if they turn up and liver biopsy patients are notorious for not having the invasive procedure and who can blame them! FDA approval for a sought after product, CE mark NHS contract anyone?

https://www.nature.com/articles/s41598-019-46442-y#:~:text=Recently%2C%20liver%20surface%20nodularity%20(LSN,death17%2C18%2C19.

Thus, the LSN quantification can be a non-invasive technique capable of detecting fibrotic changes within the liver parenchyma of NAFLD, and moreover, our data focusing on fibrosis grades of NAFLD can provide the evidence that liver surface nodularity is a useful quantitative imaging biomarker that can be used to diagnose and stage hepatic fibrosis and to predict future hepatic decompensation and death. Major strengths of the technology include the ability to assess previously acquired liver MR or CT images (making it possible to conduct large-scale retrospective population studies), wide availability and frequent use of MR and CT imaging in diagnosing from fibrosis to cirrhosis, rapid processing time (<3?minutes), no requirement for intravenous contrast media and no need for new hardware or special image acquisition procedures. In addition, the non-invasive LSN quantification method on the basis of clinical MR images has the potential in reducing the demand for invasive liver biopsy sampling or additional imaging studies in NAFLD because it can be quantified from acquired image data retrospectively and/or be applied to monitor the disease progression in follow-up data. Moreover, LSN quantification program may be capable of helping the prediction of cirrhosis compensation and death

I think many forget this is main market and not a pump and dump. Yes the company has history but the suites are selling into some of the best cancer centres in the USA, FDA approval is in the pocket for a non invasive solution, the uptake is going to be very significant and I imagine with the talks we have had this year with worldwide major businesses this process is going to be ASAP because every business wants to be first with ground breaking tech as that's where the lead sales come from and that generates long term partnerships and recurring sales. There is so much more to this than watching the SP, take a step back and look at what is in front of you, approval and sales to genuine customers and exponential growth in what is not only a hot sector due to covid but also a huge market worldwide.

Cleared out thank god, now we can concentrate on our investment and have a quieter board to do it :-)

Yes there was always going to be a point where they sold out and I think little reaction from USA market open said to some the top was reached for their short trade window. There is a hell of a lot of new share holders with much higher averages than two days ago and I am sure any under water won't be for long. The scope of not only the latest news but the whole suite is remarkable and getting very exciting with sales traction.

My prediction was a 30% rise today but the RNS kinda played havoc with the SP today so I am not going to grumble about my prediction being right as this to me was a very healthy rise and what we needed. Yes I could have traded this and had more shares but as I have said before I don't think it's the best way to make long term gains you usually end up just where you started for a lot of effort!

There have been a lot of traders in this and they need cleared out unfortunately it comes with the game. The company is a different animal now and starting from an improved MC to go forward. I know this is going to be an excellent investment over the next year and am delighted with the SP rise and what the future holds.